Article
VSTM2A suppresses colorectal cancer and antagonizes Wnt signaling receptor LRP6
1 Jan 2019
Abstract excerpt
VSTM2A is a novel antagonist of canonical Wnt signaling by directly binding to LRP6 and induces LRP6 endocytosis and degradation. VSTM2A is a potential prognostic biomarker for the outcome of CRC patients.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
